Don’t Expect Business As Usual From EMA During Transition, Says BIA Head
Executive Summary
BIA CEO Steve Bates says life science companies should not expect business as usual during the EMA’s relocation to Amsterdam, but notes that firms and industry associations are “absolutely aligned” on the need for continued close cooperation between the UK and the EU after Brexit. He also warned that firms may be holding back on investments in clinical trials in the UK.
You may also be interested in...
Brexit Hits Life Science Investment Decisions As UK Risks Exclusion From Key EU Projects
The chief executives of the APBI and the BIA have told the House of Lords’ Science and Technology Committee that Brexit uncertainty is having an impact on life science investment decisions and that the UK may not be able to benefit from key EU legislative initiatives that it helped to create.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.